Status:
TERMINATED
Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
Lead Sponsor:
University Health Network, Toronto
Conditions:
COVID-19
Pneumonia
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the safety and efficacy of the drug ruxolitinib in people diagnosed with COVID-19 pneumonia by determining the number of people whose conditions worsen (requi...
Detailed Description
Multifocal interstitial pneumonia is the most common cause of deterioration in people with COVID-19. This is attributed to a severe reaction where releases too many cytokines (proteins that play an im...
Eligibility Criteria
Inclusion
- COVID-19 infection diagnosed by nasopharyngeal sample
- Need for supplemental oxygen to maintain oxygen saturation \> 93%
- 12 years of age or older
Exclusion
- Neutrophils \< 1 x 10\^9/L
- Platelets \< 50 x 10\^9/L
- Serum total bilirubin \>2.0 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST), or alanine aminotransferase (ALT) \> 5x ULN
- Creatinine clearance (CrCl) \< 15 mL/minute
- Pregnant women
- Known HBV or HIV infection
- Signs and symptoms of Varicella Zoster Virus (VZV) infection
- Patients requiring invasive mechanical ventilation. Patients requiring non-invasive mechanical ventilation (e.g., BiPAP) are eligible.
- Patients who require supplemental oxygen support prior to COVID-19 infection.
- Patients who are on ruxolitinib or similiar drugs.
Key Trial Info
Start Date :
May 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 24 2021
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04331665
Start Date
May 21 2020
End Date
March 24 2021
Last Update
August 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9